TuesdayNov 23, 2021 12:00 pm

Study Finds Psilocybin Improves Neural, Cognitive Flexibility in Patients with Depression

A new study has found that psilocybin-assisted psychotherapy increases neural and cognitive flexibility in patients suffering from major depressive disorder. Psilocybin is the active compound found in hallucinogenic mushrooms. Research has found that the component has clinically substantial and long-lasting effects on mood and personality when used in conjunction with psychotherapy. The study was published in “Translational Psychiatry,” with researchers suggesting that psychedelic-induced increases in neural flexibility don’t always translate into cognitive improvements. The study’s authors were focused on assessing the effects of psilocybin on neural flexibility, which refers to variability in brain connectivity and activity, and cognitive flexibility, which…

Continue Reading

MondayNov 22, 2021 1:15 pm

Psilocybin Could Help Address Attachment Anxiety

Researchers are exploring whether psilocybin can be used to help individuals who feel insecure in their attachments to other people. Their findings suggest that psilocybin-assisted psychotherapy may help decrease attachment anxiety. Individuals can be insecure or secure in their attachments, with those who are insecure being either avoidant or anxious. Individuals with an avoidant style of attachment may shun intimacy and distrust other people while those with an anxious style of attachment tend to be fearful of abandonment and rejection. Researchers believe that while these styles of attachment are usually relatively stable, they may change over time. Christopher S. Stauffer,…

Continue Reading

MondayNov 22, 2021 8:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Excited for Seamless Phase 2/3 Clinical Research as Dr. Matthew Johnson Presents Interim Results of Current Smoking Cessation Study at the Psychedelic Medicine Business Event: Wonderland

Dr. Matthew Johnson discussed psilocybin for tobacco smoking cessation at this year’s Psychedelic Medicine Business Event: Wonderland, in Miami He shared preliminary findings from his recent study on substance use disorder, along with the participants’ feedback on their experience Dr. Johnson, along with Mydecine, are set to embark on their clinical study utilizing MYCO-001 for smoking cessation, set to commence in early 2022, building on the success of this recent study Mydecine is also set to support Dr. Johnson’s concurrent NIDA grant-funded study through the provision of MYCO-001 for research Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), back in September…

Continue Reading

MondayNov 22, 2021 8:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Updating Trial Protocols in Response to FDA Request as Tryp Prepares Synthetic Psilocybin Studies for Eating Disorder, Fibromyalgia Treatment

Pharmaceutical company Tryp Therapeutics is investigating the potential of synthetic psychedelic drug candidates to treat unmet medical needs The company is evaluating two drug products labeled TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome and select eating disorders The company has filed its first two INDs with the FDA for planned Ph 2a clinical trials relating to fibromyalgia and eating disorder treatments In the wake of changes recommended by the FDA to the eating disorders trial, Tryp is in the process of updating its protocols and patient consent form to meet the FDA’s expectations Tryp…

Continue Reading

FridayNov 19, 2021 1:30 pm

DEA Announces New Production Quotas for Psychedelic Substances for 2021, 2022

The DEA announced in September that it would be increasing the production quotas for Schedule I substances such as DMT, MDMA and psilocybin. This was after revealing the agency’s objective to produce more psychedelic substances for purposes of research next year. By the end of 2021, the DEA wants 6,000 grams of psilocybin to be manufactured, which is four times its last production quota. In its proposal, the agency states that the production quota for DMT and MDMA will be increased to 3,200 grams from 50 grams each. It also wants 2 million grams of cannabis to be produced this…

Continue Reading

FridayNov 19, 2021 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health

Company releases positive results from preclinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://ibn.fm/0GSuV). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of…

Continue Reading

ThursdayNov 18, 2021 11:00 am

Expert Says MDMA Could See FDA Approval by 2023

Associate professor Kelan Thomas of the Touro University California College of Pharmacy recently gave presentations during this year’s virtual Sana Symposium and the 2021 Insight conference that focused on the adverse effects of psychedelics and drug-drug interactions respectively. In a recent interview with Alana Hippensteele in the “Pharmacy Times,” Thomas was asked about his insights on the psychedelic space, with a focus on psychedelic medicine. When queried on the main points or common themes he’d observed in the field, Thomas stated that individuals were starting to consider the best practices to use psychedelics, noting that there was a lot of…

Continue Reading

WednesdayNov 17, 2021 3:00 pm

Israel to Categorize Fibromyalgia as a Disability

Fibromyalgia is a disorder characterized by widespread muscle pain, which is often accompanied by mood issues, memory problems, sleep disturbances and fatigue. Some patients also experience cognitive difficulties and physical exhaustion. Now Israel plans to recognize the disorder as a disability, with the country’s Welfare and Social Affairs announcing in October that individuals suffering from the disorder will be recognized as disabled in a couple of weeks, which will allow them to claim disability allowance. This move will make Israel among the first nations around the globe to make provisions for patients with this condition. Data from the Israeli Fibromyalgia…

Continue Reading

TuesdayNov 16, 2021 12:15 pm

Captivating Documentary Explores Psychedelics’ Role in PTSD Treatment

The focus on mental health has been growing as more research on psychedelic substances and their potential benefits as alternative treatments of various mental health conditions is conducted. Thus far, research has found that psychedelics such as mescaline, LSD and psilocybin mushrooms can help treat mental conditions, including depression, anxiety, addiction and post-traumatic stress disorder. Attention on this space has also been emphasized by the numerous literary works on the substances that are being published. A new documentary film on psychedelics, titled “Breaking Through,” which was directed and produced by Dan Laughton, a filmmaker based in London, is one of…

Continue Reading

MondayNov 15, 2021 3:00 pm

Why Voices for Psychedelic Policy Change Are Getting Louder in Michigan

The city of Ann Arbor recently held its first Entheofest event. The festival is a commemoration of the city’s measure to decriminalize entheogenic fungi and plants, which was approved last year. The event featured speeches from activists, martial artists, musicians, healers, therapists, artists, community leaders, elected officials and researchers who discussed various topics, including research, health and the history of psychedelics. In an interview, codirector of Michigan’s Decriminalize Nature chapter Julie Barron stated that maintaining a personal relationship with entheogenic fungi and plant was a human right. Organizers noted that the festival was an opportunity to advocate for the legalization…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000